Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Public ClinicalTrials.gov record NCT06162221. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Study identification
- NCT ID
- NCT06162221
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 616 participants
Conditions and interventions
Conditions
Interventions
- RMC-6291 Drug
- RMC-6236 Drug
- Pembrolizumab Drug
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
- RMC-9805 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2024
- Primary completion
- May 31, 2027
- Completion
- Nov 30, 2028
- Last update posted
- Jun 29, 2026
2024 – 2028
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Recruiting |
| City of Hope - Duarte | Duarte | California | 91010 | Recruiting |
| City of Hope - Lennar | Irvine | California | 92618 | Recruiting |
| UC Davis, Davis Comprehensive Cancer Center | Sacramento | California | 95817 | Recruiting |
| University of California, San Diego Moores Cancer Center | San Diego | California | 92037 | Recruiting |
| UCSF Medical Center - Mission Bay | San Francisco | California | 94158 | Recruiting |
| Stanford University - Stanford Cancer Institute | Stanford | California | 94305 | Recruiting |
| Colorado Health Medical Group - Medical Oncology & Hematology | Colorado Springs | Colorado | 80909 | Recruiting |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Boca Raton Clinical Research Associates | Plantation | Florida | 33322 | Recruiting |
| Cancer Specialists of North Florida | Saint Augustine | Florida | 32086 | Recruiting |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) | Detroit | Michigan | 48202 | Recruiting |
| Intermountain Health - St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | Recruiting |
| Nebraska Cancer Specialist | Grand Island | Nebraska | 68803 | Recruiting |
| New York University Langone Health | New York | New York | 10016 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Recruiting |
| Columbia University Medical Center | New York | New York | 10032 | Recruiting |
| Clinical Research Alliance | Westbury | New York | 11590 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Baptist Medical Center | Memphis | Tennessee | 38120 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Oncology Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06162221, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 29, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06162221 live on ClinicalTrials.gov.